Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference
February 18 2021 - 8:00AM
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company developing itolizumab to treat severe autoimmune and
inflammatory disorders, announced today that it will present at the
SVB Leerink 10th Annual Global Healthcare Conference taking place
February 22 – 26, 2021.
Bruce Steel, Equillium’s chief executive officer,
and Dolca Thomas, M.D., Equillium’s executive vice president of
research and development and chief medical officer, will review
each of the ongoing clinical programs in acute graft-versus-host
disease, lupus/lupus nephritis and uncontrolled asthma. Mr. Steel,
Dr. Thomas and other members of Equillium’s leadership team will be
available for one-on-one meetings during the conference.
Date: |
Thursday,
February 25, 2021 |
Time: |
11:20 AM Eastern Time | 8:20 AM Pacific Time |
Location: |
Virtual Webcast |
A live webcast of the presentation will be
available under the “Investors” section of the Company’s website at
https://ir.equilliumbio.com/events-and-presentations. An archived
replay will be available for 90 days.
About EquilliumEquillium is a
clinical-stage biotechnology company leveraging deep understanding
of immunobiology to develop novel products to treat severe
autoimmune and inflammatory disorders with high unmet medical need.
Equillium is developing itolizumab for multiple severe
immuno-inflammatory diseases, including acute
graft-versus-host-disease (aGVHD), lupus/lupus nephritis and
uncontrolled asthma.
For more information,
visit www.equilliumbio.com.
Investor ContactMichael Moore Vice
President, Investor Relations & Corporate
Communications+1-619-302-4431ir@equilliumbio.com
Media ContactKatherine Carlyle
SmithSenior Account AssociateCanale Communications+1-805-907-2497
katherine.smith@canalecomm.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024